findmyKOL
Clinical trialNCT03850964Active, not recruitingPhase 2/PHASE3Interventional

Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)

SponsorCure HHTEnrollment70AnemiaEpistaxisHHTHereditary Hemorrhagic TelangiectasiaNosebleed
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

During the Efficacy Study (Part B), the investigators will study whether Pazopanib, taken daily for 24 weeks, will reduce the severity of nose bleeds in patients with hereditary hemorrhagic telangiectasia (HHT). Patients will either be provided active drug or a placebo \[sugar - inactive pill\], and be tested for nose bleed severity throughout the trial, including particularly nose bleed duration. Investigators will also test for blood loss, as well as for safety. This study is funded by the US Department of Defense USAMRAA and FDA/OOPD.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of California - Los Angeles

    Los Angeles, California, United States

  • University of Colorado

    Denver, Colorado, United States

  • Augusta University

    Augusta, Georgia, United States

  • John Hopkins University

    Baltimore, Maryland, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, United States

  • Mayo Clinic

    Rochester, Minnesota, United States

  • Washington University

    St Louis, Missouri, United States

  • University of North Carolina

    Chapel Hill, North Carolina, United States

  • Cleveland Clinic

    Cleveland, Ohio, United States

  • University of Texas - Southwestern

    Dallas, Texas, United States

  • University of Utah Medical Center

    Salt Lake City, Utah, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Pazopanib →Placebo
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
8 May 2023
Primary completion
21 Nov 2025
Completion
31 Jul 2026
Last update posted
19 Mar 2026
Registered enrollment
70
Registry id
NCT03850964
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.